Arno Therapeutics Announces Plans to Dissolve December 22, 2017 09:10 AM Eastern Standard Time FLEMINGTON, N.J.--(BUSINESS WIRE)--Arno Therapeutics, Inc. (ARNI), a biopharmaceutical company, today announced that it has sold substantially all of its remaining assets and will be dissolving by the end of this year. Its last remaining assets were the rights to Onapristone, which it recently sold to Context Biopharma, Inc. pursuant to the terms of an asset purchase agreement. The proceeds from the sale of Onapristone will be used to satisfy Arno’s outstanding liabilities and there are not expected be any assets remaining thereafter. Arno Therapeutics: Betting On A New Course Or Buying Tickets On The Titanic? https://seekingalpha.com/instablog/470508-nsite4mom/5004254-arno-therapeutics-betting-new-course-buying-tickets-titanic Billionaires Still Believers: While the stock price has tumbled and trading volume is usually, minimal at best, investors, like George Soros, Perceptive Advisors, and OPKO (OPK) Health are staying invested. John Vincent's February 2017 article on Seeking Alpha, Tracking George Soros's Portfolio, proposed that Soros's significant state in (OTCPK:ARNI) is noteworthy. In addition to its large stake in (OTCPK:ARNI), Opko Health has "first right of negotiation to acquire Arno Therapeutics for a period of 45 days of a takeover attempt by another company. Opko was also permitted to place its Executive VP Steven Rubin on Arno's board of directors to monitor the company's progress.”
